Related by context. All words. (Click for frequent words.) 63 investigational humanized monoclonal antibody 62 Panzem R NCD 61 orally administered inhibitor 61 Maxy G# 61 JAK1 61 Xcytrin R 61 aurora kinase 61 PDX pralatrexate 61 Factor VIIa 60 Triapine R potent 60 epigenetic therapies 60 oral prodrug 60 pan HDAC inhibitor 60 isoform selective 60 BIM #A# 60 MCSP respectively 60 KSP inhibitor 60 vascular disrupting agents 60 Posiphen TM 60 OMP #R# 60 Presents Preclinical Data 59 TRX1 59 MKC# MT 59 IAP inhibitors 59 HGS ETR2 59 mitogen activated ERK kinase 59 Romidepsin 59 humanized monoclonal 59 non nucleoside inhibitor 59 tubulin inhibitor 59 HCV protease 59 AEG# 59 JAK inhibitor 58 AAG geldanamycin analog 58 selective modulator 58 alvespimycin 58 Aflibercept 58 IAP inhibitor 58 lumiliximab 58 atacicept 58 histone deacetylase inhibitor 58 polysaccharide polymer 58 BiovaxID TM 58 DPX Survivac 58 Aurora kinase inhibitor 58 Triapine 58 alpha#beta# integrin 58 CD# monoclonal antibody 58 RNA antagonists 58 HSP# inhibitor 58 Aurora Kinase 58 fosbretabulin 58 nicotinic alpha 7 58 antibody MT# 58 vosaroxin 58 Personalized Immunotherapy 58 mGlu2 3 58 oral picoplatin 58 NS#/#A protease 58 DNA intercalator 58 SPRYCEL ® 57 Kinase Inhibitor 57 NS4A 57 huC# DM4 57 PEGylated Fab fragment 57 inhibit angiogenesis 57 Luteinizing Hormone Releasing Hormone 57 Solazed TM 57 Azedra TM 57 triphendiol 57 epothilones 57 kinase inhibition 57 OvaRex R 57 Onconase 57 histone deacetylase HDAC 57 beta 1a 57 siRNA therapeutics 57 Phase IIb clinical trials 57 mediated inhibition 57 Aganocide ® 57 AQ4N 57 therapeutic monoclonal antibody 57 Sudhir Agrawal D.Phil 57 UPLYSO 57 brivaracetam 57 Collategene 57 Onalta ™ 57 Panzem 57 antisense inhibitors 57 metastatic sarcomas 57 CD# CEA 57 GSK3B 57 poly ADP ribose polymerase 57 Meets Primary Endpoint 57 Initiate Clinical Trial 57 sitaxsentan 57 Tumour Vascular Disrupting Agent 57 IMiDs R 57 Trastuzumab DM1 57 5 HT2C 57 Cloretazine R 57 sphingosine 1 57 Preclinical studies suggest 56 selective antagonist 56 Trofex TM 56 TransVax tm 56 potently inhibit 56 antibody MAb 56 novel anticancer 56 KIACTA ™ 56 Spiegelmer ® 56 ATL# [002] 56 Hsp# Inhibitor 56 IL# PE#QQR 56 Zemiva TM 56 Reports Preclinical Data 56 THR beta agonist 56 Ixabepilone 56 IMA# 56 PI3 kinase inhibitors 56 Immunotherapeutic 56 Pafuramidine 56 Exelixis XL# 56 Balaglitazone 56 KRYSTEXXA TM pegloticase 56 CB2 selective receptor agonist 56 Injectable Suspension 56 Raf kinase 56 CYC# 56 Onyx Pharmaceuticals Announces 56 TOCOSOL Camptothecin 56 Aplidin 56 PSMA ADC 56 PNP inhibitor 56 oral antiviral 56 Cloretazine 56 Omacetaxine 56 Panzem R 56 outlicensed 56 NPC 1C 56 cMET 56 Genasense ® oblimersen 56 GW# [003] 56 MEK inhibitor 56 CDK inhibitor 56 targeting PCSK9 56 TELINTRA 56 ASONEP 56 HuMax HepC TM 56 Nasdaq HALO 56 chimeric monoclonal antibody 56 multicenter Phase II 56 AMPK activators 56 Enzastaurin 56 targeted radiotherapeutic 56 Submits IND 56 TLK# 56 Neogenix 56 intranasal formulation 56 neratinib 56 Triapine R 56 mTOR mammalian target 56 alkylating agent 56 CEQ# 56 Archexin 56 Adrian Hobden Ph.D. 56 novel therapeutic antibodies 55 small molecule chemotherapeutic 55 PKC# 55 defensin mimetic antibiotic 55 Tß4 55 compound perifosine 55 PEG SN# 55 Exherin TM 55 PDE4 inhibitor 55 novel histone deacetylase 55 mGluR5 NAM 55 Combination REOLYSIN R 55 Vascular Disrupting Agent 55 alemtuzumab MS 55 arsenic trioxide injection 55 epothilone 55 receptor tyrosine kinase inhibitor 55 Squalamine 55 metaglidasen 55 molecular imaging radiopharmaceutical 55 Fx #A 55 glucokinase activator 55 ganetespib 55 hyaluronidase enzyme 55 NASDAQ NRGN 55 JAK2 inhibitor 55 incyclinide 55 Anidulafungin 55 Uvidem 55 CA4P 55 adecatumumab MT# 55 AVE# 55 reslizumab 55 midstage clinical 55 oral salmon calcitonin 55 NEUGENE R 55 MAXY VII 55 bevacizumab Avastin ® 55 Ecallantide 55 selective kinase inhibitor 55 HuLuc# 55 protein tyrosine phosphatase 1B 55 ALTROPANE R 55 Initiates Phase II 55 DNA demethylating agent 55 Novolimus 55 BENLYSTA ® 55 dextromethorphan quinidine 55 selective immunoproteasome inhibitor 55 Alzhemed TM 55 E#F# 55 TBC# 55 Allovectin 7 R 55 A3 adenosine receptor 55 HQK 55 IMiD 55 Phase 2b Clinical Trial 55 ELACYT 55 non nucleoside polymerase 55 irreversible inhibitor 55 Presents Preclinical 55 developing Zerenex ferric 55 ATHX 55 cancer immunotherapies 55 Phase IIb III 55 palifosfamide Zymafos TM 55 Inc. Nasdaq SGXP 55 docetaxel Taxotere R 55 TLR9 agonist 55 compound AEOL # 55 histamine dihydrochloride 55 FGFR 55 SinuNase TM 55 RNAi therapeutic targeting 55 Posiphen 55 Pivotal Phase III 55 PPARγ 55 orally bioavailable 55 personalized immunotherapy 55 polycythemia vera essential thrombocythemia 55 liposomal formulation 55 Resten NG 55 initiated Phase Ib 55 Ramoplanin 55 Vidaza R 55 Cerebril TM 55 HER2 antibody 55 elotuzumab 55 p# inhibitor 55 rNAPc2 55 HuMax CD4 55 generation antisense inhibitor 55 Hedgehog antagonist 55 drug conjugate 55 Manja Bouman CEO 55 volociximab 55 IgG1 monoclonal antibody 55 otelixizumab 55 Aplidin R 55 Fc fusion protein 55 Aganocide 55 human C1 inhibitor 55 deforolimus 55 Abiraterone acetate 55 Rhucin ® recombinant 55 DXL# 55 ATL# [001] 55 humanized anti 55 cyclic peptide 55 Generx ™ 55 PSN# [002] 55 calcitonin gene related 55 Apo2L 55 Cloretazine ® 55 RIGScan CR 55 dihydrofolate reductase 55 novel peptide 55 CBLC# 55 HCV RNA polymerase 55 BZL# 55 Kosan dependence 55 acetonide FA 55 muscarinic 55 candidate REP# 55 zanolimumab 55 Pancreate 55 XL# inhibits 55 GMX# 54 targets Galectin receptors 54 HGS ETR1 54 Initiates Phase 2b 54 PANVAC VF 54 outlicensing 54 Pegylated 54 Tyrosine Kinase Inhibitor 54 Darinaparsin 54 CRACM 54 hypoxia activated prodrug 54 factor VIIa 54 Nuvion 54 Maribavir 54 Safinamide 54 sunitinib Sutent 54 Trofex 54 selective adenosine 54 Troxatyl TM 54 LymphoStat B TM 54 Files IND 54 CA9 SCAN 54 multiple myeloma MM 54 oral taxane 54 Initiates Clinical 54 adenosine A2A 54 NerPharMa 54 virus HCV protease inhibitor 54 cetuximab Erbitux R 54 TOCOSOL 54 Initiates Enrollment 54 Bioral ® 54 XYOTAX TM 54 Varespladib 54 MAGE A3 ASCI 54 mapatumumab 54 multi kinase inhibitor 54 ADP receptor antagonist 54 RITUXAN ® 54 Successfully Completes Phase 54 Annamycin 54 candidate deforolimus 54 MT#/MEDI-# 54 Troxatyl 54 Elvitegravir 54 forodesine 54 huN# DM1 54 cathepsin K inhibitor 54 Navelbine R 54 NV1FGF 54 inhibitor rofecoxib 54 VNP#M 54 Lixivaptan 54 ABLYNX 54 Clolar ® 54 tumor lysis syndrome 54 selectively inhibit 54 Gleevec resistant 54 Chemophase 54 Zybrestat 54 topoisomerase II inhibitor 54 non nucleoside 54 mGluR2 NAM 54 pharmacokinetic PK study 54 Recombinant Human 54 JZP 54 inhaled AAT 54 induce apoptosis 54 selectively inhibited 54 OMP #M# 54 Receptors GPCRs 54 CrystalGenomics 54 Hematide ™ 54 midkine 54 cetuximab Erbitux 54 Dalbavancin 54 Gleevec Glivec 54 motexafin gadolinium Injection 54 Sphingomab TM 54 c Raf kinase 54 stated Michelle Berrey 54 PTP 1B 54 FK# 54 retinoic acid receptor 54 GGTase 54 Pazopanib 54 SCIB1 54 HuMax EGFr 54 mesylate 54 severe gastroparesis 54 glucagon receptor 54 Solazed ™ 54 romidepsin novel 54 Angiocept 54 Aviptadil 54 Files Investigational 54 ALK inhibitors 54 tiapamil 54 Phase Ib II 54 tezampanel NGX# 54 NS5b 54 DiLA2 liposomes 54 evaluating tivozanib 54 Teriflunomide 54 imatinib resistance 54 IMC A# 54 Nasdaq ACHN 54 pharmacokinetic interactions 54 potently inhibited 54 compound ISA# 54 Nexavar ® 54 ISTODAX 54 5 HT4 54 Epratuzumab 54 oral Azacitidine 54 gemcitabine Gemzar ® 54 MNTX 54 Granted Orphan Drug 54 ZYBRESTAT TM 54 Vitaxin 54 Azacitidine 54 ENZON 54 Campath ® 54 neuroprotectant 54 phosphate S1P 54 PTK# 54 Icatibant 54 Cinryze ™ 54 ABL inhibitor 54 INT# [002] 54 OVATURE 54 IMC #B 54 potent inducer 54 Chemokine Therapeutics 54 PDE# inhibitors 54 Nanobody 54 carbohydrate polymer 54 Bicifadine 54 Breast Cancer Assay 54 antiproliferative effects 54 antimetabolite 54 TOCOSOL R 54 PARP inhibitor 54 compound AEZS 54 HGS# 54 inhaled formulation 54 GAP #B# 54 CYP#A# CYP#D# 54 talactoferrin 54 StemEx 54 HDAC Inhibitor 54 Pharmacokinetics PK 54 CCR1 54 Neuvenge 54 tramiprosate Alzhemed TM 54 selective androgen receptor modulator 54 monoclonal anti 54 sitagliptin metformin 54 Ampligen ® 54 SinuNase ™ 54 Phase IIb Trial 54 Bezielle 54 DNA methyltransferase inhibitors 54 CCR9 54 Michel Morre DVM 54 Adenosine A2A 54 2 methoxyestradiol 54 Serostim R 54 Vascular Endothelial Growth 54 myelofibrosis polycythemia vera 54 CCR5 mAb 54 chemokine receptors 54 PDE4 54 investigational oral hepatitis C 54 rxRNA 54 TKM ApoB 54 humanized monoclonal antibodies 54 novel orally bioavailable 53 small molecule tyrosine 53 LibiGel ® 53 Pruvel ™ 53 CORT # 53 TACI Ig 53 oral Janus kinase 53 tramiprosate 53 specific lectin receptors 53 Carfilzomib 53 JAK#/JAK# 53 SNT MC# 53 vidofludimus 53 5 HT6 receptor 53 acadesine 53 Bosutinib 53 nilotinib Tasigna 53 NS5A 53 inhibit KSP 53 Myocet 53 MTP inhibitor 53 proteasome inhibitor 53 anaplastic lymphoma kinase ALK 53 agent VDA 53 ZOLINZA 53 TRO# 53 phase IIb clinical 53 cilengitide 53 targeting CD# 53 cytolytic 53 selectin antagonist 53 molecular chaperone amplification 53 thrombin receptor 53 CDK inhibitors 53 NK 1R 53 trastuzumab Herceptin R 53 SANOFI AVENTIS 53 eniluracil 53 Leukine ® 53 CMV vaccine 53 novel VDA molecule 53 registrational trial 53 MET inhibitor 53 potent suppressor 53 Phase #b/#a clinical 53 Oracea TM 53 ON #.Na 53 TNF á 53 FOLOTYN ® 53 OXi# 53 lymphoid malignancies 53 PI3K/mTOR 53 Pimavanserin 53 miRNA therapeutics 53 itraconazole Sporanox 53 obatoclax 53 PPARgamma 53 HCV polymerase 53 angiotensin receptor 53 autologous cellular immunotherapy 53 Proxinium TM 53 Ixempra 53 AGGRASTAT R Injection tirofiban 53 AMEX RGN 53 BRAF mutant 53 Cethrin R 53 Civacir 53 IMiDs ® 53 Phase IIb Clinical Trial 53 Muraglitazar 53 Tasimelteon 53 novel immunomodulatory 53 Proteasome 53 Genz # 53 oncolytic 53 Tarvacin TM 53 IFN β 53 CB2 receptor selective 53 PEG uricase 53 DACH platinum 53 Cetrorelix 53 refractory chronic lymphocytic 53 Atiprimod 53 annexin 53 potent anticancer 53 Peginterferon alfa 2b 53 sterile lidocaine patch 53 Memryte 53 R lenalidomide 53 PCK# 53 ruxolitinib 53 antidiabetic 53 lintuzumab SGN 53 lipid nanoparticle LNP 53 NYSE Amex PTN 53 mertansine 53 orBec 53 Initiates Phase III 53 Vicriviroc 53 nucleoside analog 53 PXD# 53 Allovectin 7 53 FM VP4 53 POSIDUR TM 53 Thiovir 53 malignant ascites 53 butyrylcholinesterase 53 Pruvel 53 Ceflatonin 53 CINOD 53 velafermin 53 CCX# B 53 ARRY # 53 Zenvia ™ 53 biologic therapeutics 53 Anti Tumor 53 Protein Kinase C 53 HuCAL R 53 allosteric modulator 53 Vidaza azacitidine 53 oral JAK1 53 investigational pan BCR 53 Cytotoxic 53 Begins Dosing 53 HDACi 53 Topoisomerase II 53 LEVADEX ™ 53 progressive metastatic prostate 53 GVAX ® 53 trial evaluating PRX# 53 TELINTRA R 53 Cotara ® 53 CCR5 antagonist 53 Application BLA 53 Investigational Compound 53 peripherally acting 53 anticancer compound 53 SILENOR 53 Phase #b/#a 53 Sulonex 53 CRMD# 53 ZEVALIN ® 53 PI3K inhibitors 53 soluble tumor necrosis 53 R Saizen R 53 IGF IR 53 Curaxin CBLC# 53 Aurora kinases 53 immunotoxin 53 ATL/TV# 53 Curaxin 53 systemic RNAi 53 ONCONASE R 53 NASDAQ SNTA 53 lorvotuzumab mertansine 53 overactive bladder AA# 53 tremelimumab 53 5 fluorouracil leucovorin 53 tafamidis 53 RezularTM 53 KRN# 53 rhFVIIa 53 dasatinib Sprycel ® 53 Symadex 53 selectively inhibits 53 Phase 2b Trial 53 mda 7 53 Initiate Phase 53 Parkinson disease levodopa induced 53 CXCR7 53 PF # [002] 53 NS3 protease 53 Nasdaq VRTX today 53 oncolytic virus therapy 53 Fondaparinux 53 BN# [002] 53 RhuDex ® 53 ixabepilone 53 Lenocta 53 Azedra ™ 53 5 HT2A serotonin 53 Davanat 53 BAL# [002] 53 R sipuleucel T 53 peptidic compound 53 reversible inhibitor 53 Prodarsan R 53 cysteamine bitartrate 53 Phase 2b Study 53 REGENERX BIOPHARMACEUTICALS INC. 53 EZN 53 lucinactant 53 immunotherapeutic agent 53 AVASTIN 53 eIF 4E 53 StaphVAX R 53 histone deacetylase HDAC inhibitor 53 Upregulation 53 ® C1 esterase 53 PrevOnco 53 Aurora kinase 53 PEG PAL 53 recombinant plasma 53 Panzem NCD 53 MKC# MKC# PP 53 siRNA therapeutic 53 BRAF inhibitors 53 PI3K inhibitor 53 Tarceva TM 53 ENMD # 53 novel emulsion formulation 53 PS# [001] 53 Nicole Onetto MD 53 Lpathomab 53 Octreotide 53 NEUGENE antisense 53 mineralocorticoid receptor 53 apoptosis inducer 53 LE SN# 53 NP2 Enkephalin 53 immune modulatory 53 novel topoisomerase 53 LPA1 53 Vidaza ® 53 apoptosis proteins 53 MGCD# [001] 53 FLT3 53 HuMax TAC 53 hypereosinophilic syndrome 53 mitotic kinesins 53 immuno modulatory 53 pharmacodynamic biomarkers 53 initiated Phase 1b 53 ZYBRESTAT fosbretabulin 53 HCV protease inhibitors 53 MetMAb 53 CRF1 53 systemic anaplastic large 53 SMT C# 53 Vascugel 53 tiuxetan 53 DNA hypermethylation 53 BLA filing 53 RECOTHROM R 53 CR# vcMMAE 53 TransVax ™ 53 BRILINTA 53 Oxytrex TM 53 Nasdaq NRGN 53 potently inhibits 53 PROSTVAC VF 53 REP# 53 angiogenesis inhibitor 53 VIBEX MTX 53 Fibrillex TM 53 TRAIL receptor antibodies 53 Myelodysplastic Syndrome MDS 53 ZFP Therapeutics 53 romidepsin 52 XL# XL# 52 acyclovir Lauriad R 52 novel anti infective 52 pharmacological chaperone 52 familial hypercholesterolemia FH 52 Anavex #-# 52 HGS ETR1 mapatumumab 52 cell lymphoma CTCL 52 Orally administered 52 Receives Orphan Drug Designation 52 Epidermal Growth Factor Receptor 52 Systemic Delivery 52 IIa trial 52 GLP toxicology studies 52 antifibrotic 52 MORAb 52 Ophena TM 52 bevacizumab Avastin R 52 generation purine nucleoside 52 CYT# potent vascular disrupting 52 XmAb# 52 factor TNF 52 REVLIMID R 52 anti CD3 monoclonal 52 anti CD3 52 Fibroblast 52 ocrelizumab 52 PFO migraine 52 Iloperidone 52 evaluating satraplatin 52 Mipomersen 52 lipoglycopeptide 52 velafermin belinostat 52 Akt inhibitor 52 PSN# [001] 52 TELCYTA R 52 Phase Ib clinical trials 52 candidate AQ4N 52 pan histone deacetylase 52 dopamine D2 52 Neulasta R 52 ORE# 52 Aurora kinase inhibitors 52 EndoTAG TM -1 52 ALTROPANE 52 Completes Patient Enrollment 52 #HT#A 52 VEGF inhibitors 52 Tumor Necrosis Factor 52 selective inhibition 52 trastuzumab DM1 T DM1 52 rhIGF-I/rhIGFBP-3 52 galectin 52 vascular disrupting agent 52 immune modulating 52 selective estrogen receptor modulator 52 Safi Bahcall Ph.D. 52 MOVIPREP R 52 sulfonylhydrazine class 52 Mucosal 52 MEK inhibitor RDEA# 52 DURIN TM 52 Nanobody ® 52 VitiGam 52 inhibitor PPI 52 Interferon Gamma 52 Oncolytic 52 Dr. Aiping Young 52 midstage studies 52 #D#C# 52 ibritumomab tiuxetan 52 Xanafide 52 phase IIb III 52 eritoran 52 macitentan 52 motexafin gadolinium 52 alpha#beta# 52 Targretin capsules 52 Zalbin 52 Genfit 52 inverse agonist 52 pathophysiological effects 52 DOS# 52 Guanilib 52 Cand5 52 EGF receptor 52 Tezampanel 52 phosphatidylinositol 3 52 telomerase reverse transcriptase 52 Interferon Beta 52 CLORETAZINE TM VNP#M 52 OMAPRO 52 humanized monoclonal antibody 52 RPL# 52 receptor monoclonal antibody 52 Pertuzumab 52 nalbuphine ER 52 compound INCB# 52 Phase IIb trials 52 uricase 52 HCV protease inhibitor 52 receptor inhibitor 52 sorafenib Nexavar 52 BrachySil TM 52 interferon gamma 1b 52 G#DT 52 radiation sensitizer 52 Rebif ® 52 Cytochrome P# 52 Sapacitabine 52 CRTH2 52 PRT# 52 REOLYSIN ® 52 Behcet uveitis 52 polymerase inhibitor 52 inhibit VEGF 52 immune modulator 52 Amoxicillin PULSYS Phase III 52 adenoviral 52 Potent Inhibitor 52 Urokinase 52 ALK inhibitor 52 inhibiting enzymes 52 SERMs 52 diarrhea predominant irritable 52 Nasdaq SGEN 52 SAR# [002] 52 maturation inhibitor 52 HDL Selective Delipidation 52 Elocalcitol 52 Onalta 52 Phase 2a Study 52 Genasense ® 52 humanised antibody 52 partial agonist 52 Afatinib 52 Vegenics 52 potent inhibitor 52 telaprevir VX 52 JAK inhibitors 52 Paliperidone Palmitate 52 YONDELIS R 52 Phase III Pivotal 52 triggers apoptosis programmed 52 Belinostat 52 controlled multicenter Phase 52 fibrotic disorders 52 Glufosfamide 52 5alpha reductase 52 downstream effectors 52 peptidomimetic 52 EGS# 52 tumor immunology 52 Oral Calcitonin 52 VitiGam TM 52 hormone LHRH antagonist 52 mGluR5 negative 52 TNF alpha selectively neutralizing 52 miconazole MBT 52 Aurexis R 52 mitogen activated protein 52 PI3K/Akt pathway inhibitor 52 OMNARIS HFA 52 Camvia 52 Hybridon 52 vinca alkaloid 52 mTOR inhibition 52 Present Preclinical Data 52 systemically administered 52 SUTENT ® 52 tramiprosate ALZHEMED TM 52 Harry Palmin President 52 anaphase promoting complex 52 heparanase 52 DPP4 52 catheter occlusion 52 M2 subunit 52 DCCR 52 lysophosphatidic acid LPA 52 MGN# 52 MyVax R 52 figitumumab CP 52 Tolvaptan 52 Phase IIa Clinical Trial 52 Y2 receptor 52 Pegloticase 52 anticancer agent 52 factor Xa 52 Novel Oral 52 EOquin 52 dasatinib Sprycel 52 Elan Wyeth 52 nicotinic acetylcholine receptor 52 HER1 52 omacetaxine mepesuccinate 52 PDL# 52 T#I [002] 52 mGluR5 antagonists 52 immunotherapeutic vaccine 52 Panzem ® 52 autologous dendritic cell 52 enzastaurin 52 Inc. NASDAQ AVII 52 cortisol synthesis 52 Phase III registrational 52 Plexxikon proprietary 52 immunoregulatory 52 preclinically 52 immunostimulatory 52 Olaparib 52 delta isoform 52 castrate resistant prostate cancer 52 Phase Ib study 52 Flt3 52 BiTE R 52 EGFR tyrosine kinase inhibitor 52 Rindopepimut 52 receptor agonist 52 L BLP# 52 Ziprasidone 52 activin receptor type 52 DP VPA 52 hoFH 52 CCR9 antagonist 52 riociguat 52 personalized dendritic 52 dalbavancin 52 CORLUX CORT # 52 norfloxacin 52 Bortezomib 52 valtorcitabine 52 IRX 2 52 pertuzumab 52 Supplemental Biologics License Application 52 tyrosine kinase inhibitor 52 torezolid phosphate 52 Etubics 52 cholesteryl ester transfer 52 ISTODAX ® 52 CD# antibody [001] 52 EP #R 52 torezolid 52 pharmacokinetic equivalence 52 alfa 2b 52 NTDDS 52 gefitinib Iressa 52 Bayer Onyx 52 midstage trials 52 potent cytotoxic 52 antiapoptotic 52 CRD5 52 tyrosine kinase receptor 52 BiTE antibody 52 Phenoptin 52 Phase #/#a trial 52 ZK EPO 52 Intravenous Human 52 inhalation powder 52 prescribed proton pump 52 prostate cancer AIPC 52 Androxal ® 52 Excellagen TM 52 Oncogenic 52 IL-#/# 52 selective serotonin 2C receptor 52 JAK Inhibitor 52 oral isotype selective HDAC 52 anti amnesic 52 Novel Antibiotic 52 receptor partial agonist